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Construct expression vectors of pCMV-DR4-HA and pCMV-PRMT5-Flag, and transfect them into HEK293 cells to identify the 
interaction between TRAIL-R1 and PRMT5 and the molecular mechanism underlying DR4-mediated inhibition of chemokine 
CCL20 release via TRAIL receptor 1 (DR4). Inflammatory cytokine was detected by RT-PCR and ELISA after TRAIL-R1 and/or 
PRMT5 transfection, respectively. NF-κB activity was detected by Dual Luciferase Reporter Gene Assay. ERK1/2 phosphoryla-
tion was analyzed by Western blot. PRMT5 could inhibit DR4-activated NF-κB activity and ERK1/2 phosphorylation. PRMT5 
could inhibit NF-κB activition, ERK1/2 phosphorylation as well as CCL20 secretion via binding with DR4 in HEK293 cell, sug-
gesting that PRMT5 may involve in DR4 dependent immune regulation. 
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Tumor necrosis factor (TNF)-related apoptosis-inducing 
ligand (TRAIL) is a member of the TNF superfamily [1]. 
Intensive researches have demonstrated that both mem-
brane-bound and soluble-form TRAIL rapidly induce apop-
tosis of various tumor cells with the expression of TRAIL 
receptor 1 (TRAIL-R1) or 2 (TRAIL-R2), which are also 
known as death receptor 4 (DR4) or 5 (DR5). As a matter of 
fact, TRAIL is able to bind with its five cognate receptors in 
human being: two death receptors mediating cell death by 
apoptosis, DR4/TRAIL-R1 and DR5/TRAIL-R2/killer; 
three decoy receptors, DcR1/TRAIL-R3/TRID, DcR2/ 
TRAIL-R4/TRUNDD, and secreted osteoprotegerin (OPG), 
which could bind with TRAIL, but could not mediate apop-
totic signaling. TRAIL induces apoptosis upon binding with 
death receptor in various tumor cells, but not in most nor-
mal cells [2,3]. Overexpression of death receptor in certain 
normal cell lines can also trigger apoptosis [4]. Once bind-
ing with TRAIL, the intracellular domain of death receptor 
recruits a series of adapter molecules forming death-induc- 
ing signaling complex (DISC). Then the classical apoptotic 
pathway is activated and then results in cell death. However, 
recent report [5] showed that other signaling pathway can 
be also activated by the molecules in DISC complex.  
It is shown [6] that PRMT5, an arginine methylase, can 
bind with DR4 and then inhibit the activation of NF-κB, 
which is not dependent on the methylation activity of 
PRMT5. PRMT5 results in protein methylation after trans-
lation through the regulation of certain biological gene 
transcription, RNA process. Therefore, PRMT5 plays an 
important role in regulating cell proliferation. PRMT5 can 
also affect the release of cytokines through epigenetic regu-
lation [7].  
Recently, a growing number of studies demonstrate that 
TRAIL not only induces apoptosis, but also activates non- 
apoptotic signaling pathways, such as MAPK, AKT, PKC, 
NF-κB and etc. [8,9]. There are some reports indicating that 
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TRAIL induces IL-8 and MCP-1 expression in certain cell 
lines. Our previous study shows that TRAIL promotes the 
release of CCL20 through activating the NF-κB pathway 
[10,11]. Overexpression of DR4 can also cause the secretion 
of CCL20 by similar mechanism. However, the specific 
signaling molecule has not been elucidated. In the present 
study, we explored DR4 interacting proteins and the molec-
ular mechanism regulating CCL20 release and found that 
DR4 associated with PRMT5 directly and regulated CCL- 
20 release via NF-κB pathway. 
1  Materials and methods 
1.1  Cell culture 
HEK293T cell line (human embryonic kidney cell) used in 
the study was purchased from the Cell Center, Institute of 
Basic Medical Science, Chinese Academy of Medical Sci-
ence. The cells were cultured in DMEM (Gibco®, USA) 
supplemented with 10% fetal bovine serum (FBS, Gibco®) 
at 37°C in an incubator with controlled humidified atmos-
phere containing 5% CO2. 
1.2  Plasmids and reagents 
Plasmid pCMV-PRMT5 was kindly provided by Professor 
BaoShi Lai (Institute of Genetics and Developmental Biol-
ogy, Chinese Academy of Sciences, Beijing). The DR4 ex-
pressing vector pCDNA3.1-DR4 and the NF-κB reporter 
plasmid pGL3-NF-κB were prepared previously in our lab. 
Restriction enzymes, T4 ligase, pMD18-T vector and DNA 
molecular weight marker were purchased from TaKaRa  
Co. Plasmid DNA extraction kit, PCR product purification 
kit, and gel DNA extraction kit were purchased from 
Tiangen Biological Technology Co., Ltd. (Beijing, China). 
Fetal bovine serum and DMEM medium (high glucose) 
were purchased from Gibco®. Transfection reagent 
LipofectamineTM 2000 was purchased from Invitrogen™ 
(USA). Common protein lysis buffer or protein extracting 
reagents were purchased from Gailing Co., Ltd. (Beijing, 
China). PVDF membrane was purchased from Millipore 
Corporation (USA). Standard molecular weight marker of 
pre- stained protein was purchased from Saibeisheng Co., 
Ltd (Beijing, China). Chemical luminescence kit was 
bought from General Electric Company (GE, USA). Mono-
clonal antibodies against phosphorylated ERK1/2 and 
GAPDH were purchased from Cell Signaling Technology, 
Inc. (USA). 
1.3  Construction of the recombinant plasmid 
Full-length DR4 cDNA was amplified by PCR using 
pCDNA3.1-DR4 plasmid DNA as a template, 5′-GGAAT- 
TCGGATGGCGCCACCACCAGCTAG-3′ and 5′-CGCTC- 
GAGCTCACTTGTCATCGTCGTCCTTGTAGTCCTCC- 
AAGGACACGGCAG-3′ as upstream and downstream 
primers. EcoRI and XhoI restriction sites were introduced in 
the upstream primer 5' end and downstream primer 5′ end, 
respectively. PCR reaction was set up as follows: 5 × buffer 
4 μL, dNTP 2.5 μmol, each primer 10 pmol, primer star 
enzyme 0.6 U, template DNA 100 ng, double distilled water 
to 20 μL of total reaction volume. PCR condition was as 
follows: 98°C for 6 min, 98°C for 15 s, 58°C for 40 s, 72°C 
for 2 min, 35 cycles, then 72°C terminal extension for 10 
min. PCR product was analyzed by agarose gel electropho-
resis to confirm the correct length of DR4 (1584 bp). The 
PCR product was digested by EcoRI and XhoI, respectively. 
The digestion reaction was as follows: PCR product 1 μg, 
EcoRI 10 U, XhoI 10 U, H buffer 1 μL, double distilled 
water to 20 μL of reaction volume. Gel recovered DR4 was 
ligated with pCMV-HA plasmid predigested with the same 
restriction enzymes with a concentration ratio of 1:5. The 
ligated products were transformed into DH5α competent 
cells. The cells were cultured in LB plate containing 50 
μg/mL ampicilin at 37°C for 24 h. Mono-colony was picked 
and the plasmid DNA was extracted and identified by re-
striction enzyme digestion and sequencing. The correct 
construct was named as pCMV-HA-DR4 for subsequent 
experiments. 
1.4  Co-immunoprecipitation 
PCMV-Flag-PRMT5 and pCMV-HA-DR4 plasmids were 
co-transfected into HEK293 cells. The cells were collected 
and lysed with 500 μL common protein lysis buffer con-
taining protease inhibitors on ice for 30 min. The cell lysate 
was collected by centrifugation at 12000 × g and 4°C for 10 
min. The 2 μg of rabbit anti-HA polyclonal antibody was 
added into the lysate and oscillated at 4°C overnight and 
then 30 μL protein A agarose bead suspension was added 
and oscillated at 4°C for 6 h. Agarose beads were collected 
by centrifugation at 2500 × g for 5 min and washed 3 times 
with protein lysis buffer, and then boiled for 5 min in 20 μL 
protein sample buffer followed by SDS-PAGE. The target 
band was detected by Western blot assay using anti-HA 
monoclonal antibody.  
1.5  Western blot assay  
Cells were harvested and washed twice with cold PBS, and 
then lysed in 50 μL ice-cold lysis buffer for 30 min. Protein 
samples were boiled for 10 min in sample buffer and sub-
jected to SDS-PAGE. The proteins in the gel were trans-
ferred on polyvinylidene difluoride membrane (PVDF). The 
membrane was blocked with skimmed milk at room tem-
perature for 1 h and then incubated in the first antibody di-
lution at 4°C overnight, and then washed 3 times with 
TBST buffer for 10 min. The membrane was then incubated 
with the peroxidase labeled secondary antibody and washed 
with TBST buffer. The interested protein band was visual-
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ized by using ECL system and exposed to Kodak X-omat 
BT film [12]. 
1.6  Dual-luciferase reporter assay 
The dual-luciferase reporter assay was carried out according 
to the manufactural instruction of Promega Corporation 
(USA). Briefly, 293T cells were co-transfected by reporter 
and internal control plasmids in a ratio of 50:1. After 48 h 
cultivation, cells were collected and lysed. The lysate was 
added into the wells (100 μL/well) of 24-well plate and 
mildly oscillated for 15 min. The samples were placed at 
room temperature before measuring and 25 μL LARII was 
added to each well. Set delay for 2 s, measure for 10 s. 25 
μL Stop&Glo reagent was continually added and mixed. 
Fluorescence of the internal control Renilla reniformis lu-
ciferase was measured. Firefly luciferase activity was 
standardized by the sample with the Renilla reniformis lu-
ciferase activity. Then the relative luciferase activity was 
calculated.  
1.7  Inflammatory cytokine detection by RT-PCR and 
ELISA 
Cells were co-transfected according to the manufatural in-
struction of LipofectamineTM 2000 specification with: (1) 
pCMV-Flag (2 µg) and pCMV-HA (2 µg); (2) pCDNA3.0- 
DR4 (2 µg) and pCMV-Flag (2 µg); (3) pCMV-Flag (2 µg) 
and pCMV-HA-DR4 (2 µg); (4) pCMV-Flag-PRMT5 (2 µg) 
and pCMV-HA (2 µg); (5) pCMV-Flag-PRMT5 (2 µg) and 
pCMV-HA-DR4 (2 µg). RNA extraction and cDNA synthe-
sis were referred to the experimental guidance of Promega 
Corporation. PCR primers for each cytokines were as fol-
lows: IL8, 5′-ACTGAGAGTGATTGAGAGTGGACC-3′, 
5′-AACCCTCTGCACCCAGTTTTC-3′; TNF-, 5′-CCAG- 
GGACCTCTCTCTAATCAGC-3′, 5′-CTCAGCTTGAGG- 
GTTTGCTACA-3′; CCL20, 5′-AGAGTTTGCTCCTGGC- 
TG-3′, 5′-GGATGAAGAATACGGTCTGTG-3′; MIP-1β, 
5′-GGAAGCTTCCTCGCAACTTTG-3′, 5′-GCTCAGGT- 
GACCTTCCCTGAA-3′; GAPDH, 5′-CCGTCTAGAAA- 
AACCTGCC-3′, 5′-AGCCAAATTCGTTGTCATACC-3′. 
All PCRs were run for 40 cycles. The PCR for internal con-
trol GAPDH was run for 30 cycles. ELISA was carried out 
according to the manufactural instruction (R&D Corpora-
tion, USA). 
2  Results 
2.1  PRMT5 suppresses mRNA expression of cytokine 
First all, we checked the influence of DR4 and/or PRMT5 
over-expression in inflammatory cytokine expression. 
HEK293T cells were transfected with pCMV-Flag-PRMT5 
and/or pCMV-HA-DR4 or pCDNA3.1-DR4. Inflammatory 
cytokine mRNA expression was detected by RT-PCR. As 
shown in Figure 1, the expressions of CCL20, IL-8, TNFα, 
MIP-1α, and MIP-1β were significantly increased in DR4 
over-expression cells, but suppressed markedly in PRMT5 
and DR4 over-expressed cells. However, there was no 
change in the cytokine expression observed in PRMT5- 
overexpressed cells, suggesting that PRMT5 suppresses the 
mRNA expression of the inflammatory cytokine. 
2.2  DR4 binds with PRMT5  
Next we investigated whether DR4 interacts with PRMT5 
by co-immunoprecipitation followed by Western blot assay. 
As shown in Figure 2, anti-DR4 antibody immunoprecipita-
tion could well pull down PRMT5 in pCMV-HA-DR4 and 
pCMV-Flag-PRMT5 co-transfected cells, suggesting that 
DR4 binds with PRMT5, which provides a molecular 





Figure 1  The mRNA expression of inflammatory cytokine in the 
HEK293T cells with DR4 and/or PRMT5 over-expression. HEK293T cells 
were transfected with pCMV-HA-DR4 or pCDNA3.0-DR4 and/or 
pCMV-Flag-PRMT5, respectively. The mRNA expression was detected by 
RT-PCR.  
 
Figure 2  DR4 binds with PRMT5 in HEK293T cells identified by co- 
immunoprecipitation and Western blot assay. HEK293T cells were trans-
fected with pCMV-HA-DR4 (DR4) and/or pCMV-Flag-PRMT5 (PRMT5). 
The cell lysates were subjected to co-immunoprecipitation and Western 
blot assay. 
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2.3  PRMT5 suppresses CCL20 protein expression 
Detection of CCL20 protein expression by ELISA showed 
that CCL20 protein expression was significantly increased 
in the cells with DR4 over-expression, while decreased in 
the cells with DR4 plus PRMT5 over-expression, but made 
no change in the cells with PRMT5 over-expression (Figure 
3), suggesting that PRMT5 inhibits CCL20 expression. 
2.4  PRMT5 inhibits NF-κB activity 
We further analyzed NF-κB activity by Dual-luciferase re-
porter gene assay. As shown in Figure 4, NF-κB activity 
was activated in DR4 over-expressed cells, which was con-
sistent with our previous report [11]. However, the activity 
of NF-κB was inhibited in PRMT5 over-expressed cells. 
These data provide an evidence that PRMT5 inhibits 
CCL20 expression via inhibiting NF-κB activation. 
2.5  PRMT5 blocks ERK1/2 phosphorylation  
Finally, we further tested phosphorylation of ERK1/2 in the 
cells with DR4 plus PRMT5 over-expression by Western 
blot assay. As shown in Figure 5, phosphorylation of ERK1/2 
was increased in the cells with DR4 over-expression, but 
blocked markedly in the cells with PRMT5 over-expression.  
 
 
Figure 3  CCL20 expression in HEK293T cells with over-expression of 
DR4 and/or PRMT5. HEK293T cells were transfected with pCMV-HA- 
DR4 and/or pCMV-Flag-PRMT5, respectively. The cells were lysed with 
lysis buffer and the lysates were then subjected to ELISA for CCL20 ex-
pression detection. *P<0.05. 
 
Figure 4  NF-κB activity in HEK293T cells with DR4 and/or PRMT5 
over-expression. NF-κB activity was depicted by the relative luciferase 
activity detected by using Dual-luciferase reporter gene system. *P<0.05.  
 
Figure 5  ERK1/2 phosphorylation in HEK293T cells with DR4 and/or 
PRMT5 over-expression detected by Western blot assay.  
Taken together, these data demonstrate that PRMT5 sup-
presses CCL20 secretion via inhibiting ERK1/2 phosphory-
lation in NF-κB pathway, suggesting that PRMT5 might be 
involved in DR4-dependent immune regulation. 
3  Discussion 
In recent ten years, TRAIL research has been focused on its 
role in inducing tumor cell apoptosis and cancer therapy. 
However, little is known about its physiological function 
and the molecular mechanism. Our previous study reported 
that TRAIL could activate NF-κB pathway and induce in-
flammatory cytokine storm, especially, an important chem-
okine CCL20 expression [12]. It is reported that PRMT5 
interacted with DR4 in Hela cells and, therefore, interfered 
the activity of NF-κB [7], suggesting that PRMT5 might be 
recruited into death inducing signal complex (DISC) and 
further regulate cytokine release. 
CCL20 is a member of chemokine family and is related 
to the severity of pneumonia and chronic obstructive pul-
monary disease (COPD) [13]. CCL20 is highly expressed in 
colon cancer and scleroderma [14,15]. CCL20 could induce 
immune cell chemotaxis and tumor cell migration by inter-
acting with its receptor CCR6 [16]. TRAIL plays an im-
portant role in these disease models. Up-regulated TRAIL 
or recombinant TRAIL combined with chemotherapy could 
improve the therapeutic efficacy in these diseases. These 
data suggest that TRAIL may have a physiological function 
against tumors besides inducing apoptosis. 
In the present study, we have demonstrated that PRMT5 
interacts with DR4, suggesting that PRMT5 may regulate 
the function of DISC in DR4-mediated signaling pathway. 
In TNFα-stimulated cells, RIP1 and TRAF2 would be re-
cruited in the DISC and activated NF-κB. TRAIL, the 
member of the TNF super-family, may have the similar 
function to TNFα. While DR4 binds with TRAIL, it could 
recruit RIP1 in its downstream DISC complex. TRAF2 may 
be also recruited in the DISC and activates NF-κB pathway. 
PRMT5 may competitively bind with DR4, and therefore, 
suppresses NF-κB activation. We also observed that DR4 
over-expression activated NF-κB, but DR4 plus PRMT5 
over-expression suppressed NF-κB activation, and CCL20 
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expression was decreased accordingly. It suggests another 
possibility that PRMT5 might suppress NF-κB activity di-
rectly, which needs to be further clarified.  
We have showed that ERK1/2 phosphorylation could be 
up-regulated in DR4 over-expressed cells, but suppressed in 
DR4 and PRMT5 over-expressed cells, indicating that 
MAPK/P38 pathway is involved in TRAIL-induced chemo-
kine release. In the fact, many reseachers have reported that 
MAPK pathway widely participates in inflammatory cyto-
kine release [17], which includes the cytokines presented in 
Figure 1, i.e., CCL20, MIP-1α, MIP-2Β, IL-8, and TNFα, 
indicating that TRAIL not only induces apoptosis, but also 
regulates cytokine release.  
CCR6, the receptor of CCL20, is highly expressed in 
many immune cells, such as lymphocyte and macrophage. 
CCL20-CCR6 axis plays an important role in immune cell 
chemotaxis and migration. TRAIL or DR4 over-expression 
up-regulated CCL20 release, suggesting that CCL20-CCR6 
interaction may involve in tumor-related immune cell infil-
tration or chemotaxis. The function and molecular mecha-
nism of these immune cells in tumor growth need to be fur-
ther clarified. This observation that TRAIL regulates 
CCL20 expression opens a novel direction on TRAIL 
physiological function research.  
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